Allogene Therapeutics (ALLO) Intangibles (2018 - 2019)
Allogene Therapeutics (ALLO) reported Intangibles of $151000.0 for Q4 2019, down 79.97% on a YoY basis from $754000.0 in Q4 2018, and down 49.83% sequentially from $301000.0 in Q3 2019.
Allogene Therapeutics (ALLO) Intangibles (2018 - 2019) Analysis & Trends
Allogene Therapeutics (ALLO) has 2 years of Intangibles data on file, last reported at $151000.0 in Q4 2019.
- For the quarter ending Q4 2019, Intangibles fell 79.97% year-over-year to $151000.0; the trailing twelve-month figure through Dec 2019 stood at $151000.0 (down 79.97% YoY), and the FY2019 full-year result was $151000.0, down 79.97% from the prior year.
- Intangibles slipped to $151000.0 in Q4 2019, from $301000.0 in the prior quarter.
- In the past five years, Intangibles ranged from a high of $904000.0 in Q3 2018 to a low of $151000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 16.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 11,640.44 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 61.68 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.92 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 418.50 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.29 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 266.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 55.80 Mn |
| 10 | Allogene Therapeutics | 437.33 Mn | 437.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 151,000.00 |
| Sep 30, 2019 | 301,000.00 |
| Jun 30, 2019 | 452,000.00 |
| Mar 31, 2019 | 603,000.00 |
| Dec 31, 2018 | 754,000.00 |
| Sep 30, 2018 | 904,000.00 |